---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-004162"
form_type: "8-K"
ticker: "CYPH"
cik: "0001509745"
company_name: "CYPHERPUNK TECHNOLOGIES INC."
filed_at: "2024-01-16T23:59:59+00:00"
generated_at: "2026-06-06T23:07:56.119185+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Leap Therapeutics reports 30% ORR and 93% DCR in Part A of DeFianCe study for DKN-01 in second-line CRC

## Summary
- Across 27 evaluable microsatellite stable CRC patients: ORR 30%, DCR 93%, median PFS 6.3 months.
- Left-sided tumors: 33% ORR, 100% DCR, preliminary median PFS 8.6 months.
- Rectal/rectosigmoid subgroup (n=15): 46% ORR, 100% DCR, preliminary median PFS 9.4 months.
- DKN-01 plus bevacizumab and chemotherapy well-tolerated; majority of related events Grade 1/2.
- Part B of study enrolling well, expected to complete enrollment mid-2024; conference call January 23.

## SEC filing metadata
- accession: 0001104659-24-004162
- form_type: 8-K
- ticker: CYPH
- cik: 0001509745
- company_name: CYPHERPUNK TECHNOLOGIES INC.
- filed_at: 2024-01-16T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1509745/000110465924004162/0001104659-24-004162-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1509745/000110465924004162/tm243430d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-004162
- JSON: https://secwatch.observer/filing/0001104659-24-004162.json
- Plain text: https://secwatch.observer/filing/0001104659-24-004162.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.